The last patient visit was completed in Stayble Therapeutics' herniated disc study
Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the last patient visit has been completed in the phase 1b study involving patients with pain caused by herniated discs. This company follows the previously communicated timeline and expects to present results during the fourth quarter of 2024.A total of 25 patients were included, and 22 completed their 6-month follow-up, meaning the goal of having at least 18 evaluable patients in the study has been achieved. CEO Andreas Gerward commented: "I am very proud that we have conducted our clinical study according